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Abstract: It is widely recognized that the microorganisms inhabiting our gastrointestinal tract—the
gut microbiota—deeply affect the pathophysiology of the host. Gut microbiota composition is mostly
modulated by diet, and gut microorganisms communicate with the different organs and tissues of
the human host by synthesizing hormones and regulating their release. Herein, we will provide
an updated review on the most important classes of gut microbiota-derived hormones and their
sensing by host receptors, critically discussing their impact on host physiology. Additionally, the
debated interplay between microbial hormones and the development of cardiovascular disease will
be thoroughly analysed and discussed.
Keywords: gut microbiota; cardiovascular disease; atherosclerosis; SCFA; bile acids; neurohormones;
hormones; metabolism
1. Introduction
Humans have evolved to harbour trillions of microorganisms on and within their body. Consortia
made up of bacteria, fungi, protozoa, and viruses inhabit several areas of the body such as the lungs [1],
urinary tract [2], vagina [3], and skin [4], although the largest microbial community is found in
the intestine [5]. The gut microbiota is mainly composed of bacteria and the dominant phyla are
Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, and Verrucomicrobia [3].
The composition of gut microbiota and the relative amount of these bacterial phyla can be
modulated by endogenous and exogenous factors [6,7], including maternal prenatal factors [8],
delivery mode [9], host genetics [10–12], host immune response [13], breast- or formula-feeding [14],
dietary habits [15,16], the administration of antibiotics and other drugs [17,18], and environmental
exposure [19] (Figure 1).
Additionally, each bacterial species can be further divided into clearly defined, discrete subspecies,
or into a gamut of micro-organisms shaped by continuous microbial genetic variations [20]. Within the
small intestine, the bacterial density is limited by the presence of oxygen [21], bile acids [22], and
antimicrobial peptides [23], whereas in the large intestine, more favorable conditions—including a
lower concentration of antimicrobials and a slower transit time—determine the highest bacterial load
of the body [5].
The past 15 years have greatly increased our knowledge of microbial genes (the microbiome)
and products, thanks to culture-independent “omic” techniques [24]. Nowadays, it is commonly
believed that the metabolic capacity of the gut microbiota largely exceeds that of the human host: this
assumption stems from a catalogue of 10 million non-redundant microbial genes (vs. 30,000 human
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genes) identified from over 1200 human faecal microbiomes collected in Europe, the United States, and
China [25]. Although the biological function of the majority of bacterial gene products remains poorly
defined, it has been widely demonstrated that the gut microbiota can influence the host in many ways:
it modulates the immune defence [26] and provides protection against pathogens [27]; metabolizes
bile acids (BAs) and xenobiotics [28,29]; it regulates not only intestinal homeostasis [30,31], but also
brain function [32] and bone density [33]; it synthesizes amino acids, short chain fatty acids (SCFA)
and vitamins [34]. The gut microbiota is also well-recognized for its role in regulating the metabolism
of the host [35–40].Nutrients 2020, 12, x FOR PEER REVIEW 2 of 31 
 
 
Figure 1. The composition of gut microbiota is influenced by exogenous and endogenous factors. 
While diet and host genetics have the largest influence on the makeup of microbiota, several other 
factors contribute to the selection of the bacterial species that live within the human gut (grey arrows). 
In turn, the gut microbiota is able to interact and influence some of those factors (blue arrows). 
Additionally, each bacterial species can be further divided into clearly defined, discrete 
subspecies, or into a gamut of micro-organisms shaped by continuous microbial genetic variations 
[20]. Within the small intestine, the bacterial density is limited by the presence of oxygen [21], bile 
acids [22], and antimicrobial peptides [23], whereas in the large intestine, more favorable 
conditions—including a lower concentration of antimicrobials and a slower transit time—determine 
the highest bacterial load of the body [5]. 
The past 15 years have greatly increased our knowledge of microbial genes (the microbiome) 
and products, thanks to culture-independent “omic” techniques [24]. Nowadays, it is commonly 
believed that the metabolic capacity of the gut microbiota largely exceeds that of the human host: this 
assumption stems from a catalogue of 10 million non-redundant microbial genes (vs. 30,000 human 
genes) identified from over 1200 human faecal microbiomes collected in Europe, the United States, 
and China [25]. Although the biological function of the majority of bacterial gene products remains 
poorly defined, it has been widely demonstrated that the gut microbiota can influence the host in 
many ways: it modulates the immune defence [26] and provides protection against pathogens [27]; 
metabolizes bile acids (BAs) and xenobiotics [28,29]; it regulates not only intestinal homeostasis 
[30,31], but also brain function [32] and bone density [33]; it synthesizes amino acids, short chain fatty 
acids (SCFA) and vitamins [34]. The gut microbiota is also well-recognized for its role in regulating 
the metabolism of the host [35–40]. 
Importantly, the gut microbiota not only contributes to host physiology, but, on the other side, 
alterations in the distribution of the species that make up the intestinal microbiota (dysbiosis) can 
predispose to a variety of chronic diseases, including inflammatory bowel disease [41], gastric ulcers 
[42], non-alcoholic fatty liver disease [43], obesity [44], metabolic syndrome [45], cancer [46], and 
several neurologic disorders [47]. The multiplicity of interactions between the gut microbiota and the 
pathophysiology of the host clearly indicates that the gut microbiota does not limit its effects to the 
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and several neurologic disorders [47]. The multiplic ty of interactions bet en the gut microbiota a d
pat ophysiology of the host clearly indicates that the gut microbiota does not limit its effects to the
intestinal milieu but is able to influence distant organs and pathways. Recently, it has b en esta lished
that the g t microbiota can a so affect th host als through hormone secretion, and by the production
of metabolites with the ability to regulate hor one release [48]. In thi respect, the gut microbiota
can be fully considered as an endocrine organ. The enormous dive sity of microbiota in terms of
bacterial spec s allows fo the production of a wide nu ber f pro ucts with potential endocrine
functions. The mos investigated functions are reviewed here below (Figure 2). Si ce microbiota affect
the host metabolism, and metabolic dis rde s are well-known contributors in the developmen of
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atherosclerosis and related cardiovascular diseases (CVD), the last part is focused on the endocrine
role of gut microbiota in CVD.
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2. The Gut microbiota as an Endocrine Organ
2.1. Neurohormones
The ability of bacteria to produce neurohormones—including catecholamines, serotonin and
gamma-aminobutyric acid (GABA)—has been known for many years [49].
Catecholamines: considerable concentrations of catecholamines can be found in the gut lumen [50].
In vitro experiments have demonstrated that several bacterial species are sensitive to catecholamines,
with Gram-negative bacteria being generally more responsive than Gram-positive bacteria. Several
pathogens, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus
aureus improve their growth in the presence of norepinephrine (NE), primarily through increased iron
acquisition [51]. Additionally, exposure to stress hormones may enhance the expression of those genes
responsible for bacterial virulence [52].
The microbiota not only responds to catecholamines, but also plays a role in their biosynthesis
and catabolism. Interestingly, the absence of bacteria in germ-free mice is associated with lower
NE levels in the cecal lumen, and microbiota colonization is able to restore the cecal content of
NE [50]. It is known that several bacterial strains have the capability to produce dopamine (DA) and
NE [53]. Furthermore, bacterial β-glucuronidase of the gut microbiota can convert biologically inactive
glucuronide-conjugated DA and NE into the biologically active free forms [53]. Based on these results,
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the gut microbiota seems to be a determinant of catecholamine concentration in the gut lumen. It has
still to be established to which extent gut bacteria directly secrete catecholamines in vivo and/or if the
microbiota can modulate catecholamine host production. Interestingly, it has been shown that the
gut microbiota affects catecholamine turnover in the central nervous system: in germ-free mice, an
accelerated metabolism of DA, NE and also serotonin was detected in brain, and was associated with
changes in behaviour—i.e., increased motor activity and reduced anxiety [54].
Serotonin: serotonin (5-hydroxytryptamine) is known to regulate several physiological processes
throughout the body, including neurological functions, gastrointestinal secretion and peristalsis [55,56].
Despite the relevant role of central serotoninergic mechanisms, the brain contains low relative
concentrations of serotonin. The vast majority of it—about 95%—is, in fact, produced in the bowel by
the enterochromaffin cells (EC), which express tryptophan hydroxylase-1 (TPH1), the rate-limiting
enzyme in serotonin’s biosynthesis from the amino acid tryptophan [57]. Even though some bacterial
species—such as Escherichia coli—are known to synthesize tryptophan, there is no evidence that
the bacterial community makes a significant contribution toward its production in humans [58].
Besides serotonin production, tryptophan is processed by the microflora of the gastrointestinal tract
into ligands of the aryl hydrocarbon receptors (AHRs) [59], as well as into kynurenine and related end
products [60]. EC-secreted serotonin reaches the intestinal lumen and the blood, but it cannot cross the
blood-brain barrier [55].
Several studies have demonstrated that gut microbiota can modulate host serotonin concentration.
First of all, a metabolomic analysis showed that blood serotonin levels are lower in germ-free mice and
are normalized after microbiota colonization [61]. Different bacteria have the capability to directly
produce serotonin, although the possible relevance of this property in vivo is yet to be determined [49].
Additionally, similarly to catecholamines, serotonin undergoes deconjugation by the bacterial enzymes
of the gut microbiota with the formation of the biologically-active free molecule [62]. However, the
microbiota is believed to influence host serotonin levels, mostly through the secretion of SCFA or BAs
(see below), which stimulate the EC to produce serotonin, specifically by increasing the expression of
TPH1 [63,64].
Gamma-aminobutyric acid (GABA): GABA is an inhibitory neurotransmitter playing a role not
only in the central nervous system, but also in the control of several processes occurring in the gut,
including the regulation of intestinal motility, gastric emptying and acid secretion [65].
The microbiota seems to affect peripheral GABA levels, as shown in germ-free animals, where
GABA concentrations in colonic lumen and plasma were lower—whereas cerebral concentrations were
unchanged—compared with those of colonized mice [66].
Gut bacteria have a strong, bidirectional relationship with GABA. GABA production, originating
from the decarboxylation of glutamate, has been reported for a large number of bacterial species [49]
and plays a relevant role in bacterial physiology, since it contributes to the maintenance of intracellular
pH homeostasis [67]. Subspecies of Escherichia coli can grow on GABA as sole carbon and nitrogen
source [68]. Furthermore, some intestinal bacteria can only grow when other bacteria, such as
Bacteroides fragilis, act as a helper bacterium to produce GABA—the only substrate they can grow
onto [69]. Very recently, the whole genomic sequences of ~1200 bacterial species identified in the human
gut were evaluated against all the known GABA-consumption and -production enzyme sequences.
Approximately 100 species were found to be able to synthesize GABA, ~200 possessed the enzymatic
machinery to consume it, and ~210 were able to both produce and consume it [69].
In an attempt at assessing whether the administration of probiotic bacteria could affect brain
function, Lactobacillus rhamnosus JB-1 was chronically administered to healthy mice and found to
reduce depressive- and anxiety-like behaviour. Interestingly, this effect was associated with changes
in the expression of cerebral GABA receptors [70]. More recently, the same research group showed,
using magnetic resonance spectroscopy, that Lactobacillus rhamnosus JB-1 treatment in mice was able
to increase GABA cerebral concentration by about 25% [71]. Despite these promising experimental
results, a clinical study failed to show any effect on stress and cognitive performance by Lactobacillus
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rhamnosus JB-1 given to healthy male volunteers [72]. Other studies will be needed to evaluate the
possible effects of probiotics on stress-related disorders in healthy or diseased subjects.
2.2. Bile Acids
BAs are soluble products derived from the catabolism of highly insoluble cholesterol. Notably,
almost all cells are able to synthesize cholesterol from acetate or get it from the diet (~70% and ~30%,
respectively), but only the liver can eliminate cholesterol via secretion into the bile, unmodified, or
converted into BAs. The whole-body cholesterol balance is thus finely tuned by the interactions among
cholesterol synthesis, absorption and excretion [73].
In hepatocytes, the biosynthesis of the two primary BAs, cholic acid (CA) and chenodeoxycholic
acid (CDCA), occurs via two different series of enzymatic reactions: the classical pathway, initiated
by the enzyme cholesterol 7a-hydroxylase (CYP7A1), and the alternative pathway initiated by
sterol-27-hydroxylase (CYP27A1) [74]. The 27-hydroxycholesterol is further hydroxylated by oxysterol
7a-hydroxylase (CYP7B1). The CA:CDCA ratio is determined by the sterol 12a-hydroxylase (CYP8B1),
which is required for CA synthesis [75]. Interestingly, the expression of CYP7A1, CYP7B1, and
CYP27A1, but not that of CYP8B1, is regulated by gut bacteria [76].
CA and CDCA are then extensively conjugated in a two-step process to either glycine (75%)
or taurine (25%), transported into bile via the bile salt export pump (BSEP), and subsequently
stored in the gallbladder until their release into the duodenum after the ingestion of a meal [28].
The conjugation process increases the water-solubility and detergent properties of BAs, thus facilitating
the emulsification and absorption of dietary cholesterol, triglycerides and fat-soluble vitamins [77].
Over 90% of conjugated BAs are reabsorbed in distal ileum via the apical sodium-dependent bile
acid transporter (ASBT or SLC10A2) located on the enterocyte brush border. Once in the enterocyte,
BAs are transported to the basolateral membrane by the intestinal bile acid-binding protein (IBABP)
and then eﬄuxed by OST-α/β into the blood to be recirculated via the portal vein to the liver [74,78].
The bacterial metabolism of the BAs that are not reabsorbed represents one of the most intriguing
relationships linking gut microbiota to host physiology. Microbial deconjugation removes glycine
or taurine from the sterol core of the primary BAs, generating less soluble, unconjugated BAs and
prevents their ASBT-mediated reuptake from the small intestine, thus increasing the excretion of free
BAs into faeces [79]. The deconjugation is catalyzed by bile salt hydrolases (BSHs), enzymes that are
expressed by numerous strains belonging to several bacterial genera, including the Gram-positive
Bifidobacterium, Lactobacillus, Clostridium and Enterococcus and the Gram-negative Bacteroides [80–82].
Because bile acids are toxic molecules to bacteria due to their acidic nature and detergent-like
properties [83], it has been hypothesized that the wide distribution of BSHs may indicate that BAs
deconjugation facilitates the symbiosis between gut bacteria and the human host [84,85]. In addition,
it has been proposed that the released glycine and taurine could represent a source of nutrients
for bacteria, including glycine as an energy, carbon, and nitrogen source, and taurine as a sulphur
source [79].
A small number of deconjugated secondary bile acids can be absorbed from the gut through
passive diffusion, joining the enterohepatic circulation and possibly acting as signaling molecules in
the host. Deconjugated primary bile acids descend to the colon, where they can be 7-dehydroxylated,
and oxidized/epimerized by the intestinal microbiota, markedly increasing the diversity of BAs
(Table 1) [86].
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Table 1. The human bile acids and their receptors.
Human Bile Acid Pool
Primary BAs CA, CDCA
Secondary BAs LCA, DCA, UDCA, iso-BAs, allo-BAs, keto-BAs
Receptor Affinity
FXR CDCA > DCA > LCA > CA > UDCA
TGR5 LCA > DCA > CDCA > CA > UDCA
PXR LCA
VDR LCA
S1PR2 Conjugated BAs (T-CA, G-CA, T-DCA, G-DCA, T-UDCA)
CA: cholic acid; CDCA: chenodeoxycholic acid; LCA: lithocholic acid; DCA: deoxycholic acid; UDCA:
ursodeoxycholic acid; T-: taurine conjugated; G: glycine conjugated.
The 7-dehydroxylation generates the secondary BAs lithocholic acid (LCA) from CDCA and
deoxycholic acid (DCA) from CA in humans. Although LCA and DCA are absorbed to some extent,
7-dehydroxylation is the most important bacterial biotransformation, with LCA and DCA being the
two predominant bile acids in human faeces [79,87]. Bacteria able to perform this reaction belong
to the Clostridium (clusters XIVa and XI) and Eubacterium genera, both included in the Firmicutes
phylum [79,88–90].
The oxidation and epimerization of the 3-, 7-, or 12-hydroxyl groups of BAs are carried out by the
hydroxysteroid dehydrogenases (HSDHs), which were found in Actinobacteria, Proteobacteria, Firmicutes,
and Bacteroidetes [91–95]. It has been hypothesized that bacteria epimerize BAs to make them less toxic
and harmful to bacterial membranes [73]. In rodents, the secondary bile acids generated by the activity
of gut microbiota are murideoxycholic acid (MDCA), omega-MCA (ωMCA), hyodeoxycholic acid
(HDCA), and hyocholic acid (HCA).
Germ-free mice have larger gallbladders and higher levels of BAs than those of conventionally
raised mice, with a differential bile acid profile characterized by an increased prevalence of conjugated
primary BAs and absence of secondary BAs [96].
The fraction of BAs that is not reabsorbed into enterohepatic circulation and not excreted with the
faeces, can enter the systemic circulation through transcellular passive or active mechanisms [97].
Circulating BAs act as signaling molecules able to regulate several processes such as
their own synthesis [98], glucose and energy homeostasis [99–101], intestinal peristalsis [102],
inflammation [103,104], gut microbiota composition [105], and skeletal muscle mass [106].
The systemic signaling activity of BAs is primarily mediated by two receptors, the farnesoid X
receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5) (Table 1) [107–109]. Additionally,
the pregnane X receptor (PXR) [110], the sphingosine-1-phosphate receptor 2 (S1PR2) [111], and the
vitamin D receptor (VDR) [112], can be activated by BAs or their metabolites.
FXR is widely expressed, but plays a pivotal role in liver, ileum [113,114], kidney [115], white
adipose tissue (WAT) [116] and heart [117].
In the liver, bile acid-activated FXR forms a heterodimer with retinoic X receptor (RXR) and
suppresses the expression of CYP7A1, thus reducing the hepatic conversion of cholesterol into
BAs [108,118]. At the same time, in the ileum, FXR induces the expression of circulating fibroblast
growth factor 19 (FGF19); FGF19 reaches the liver with portal blood, where it binds to the FGF
receptor 4 and inhibits the expression of both CYP7A1 and CYP8B1, further reducing the synthesis of
BAs [108,119].
In addition, as mentioned above, the composition of gut microbiota can be deeply influenced by
BAs and when the bile flow into the intestine is hampered, bacterial overgrowth and translocation of
bacteria in the small intestine occur [120,121]. Interestingly, in addition to their detergent properties,
BAs can prevent bacterial growth via the FXR-mediated transcription of antimicrobial agents [122].
TGR5 is ubiquitously expressed with high expression in nonparenchymal cells of the liver [123],
intestinal enteroendocrine cells that secrete the incretin hormone glucagon-like peptide-1 (GLP-1),
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enteric neurons [123,124], placenta, lung, spleen, WAT, brown adipose tissue, skeletal muscle,
and bone marrow [125–127]. TGR5 is mainly activated by the BAs LCA and DCA [126,128].
In enteroendocrine L cells, TGR5 activation promotes the release of GLP-1, whereas in brown
adipose tissue and skeletal muscle, it promotes energy expenditure via the augmented activity of
type-2 iodothyronine-deiodinase which, in turn, upregulates the expression of uncoupling proteins 1
and 3 (UCP1 and UCP3) [109]. Taken together, the effects described above improve glucose metabolism
and insulin sensitivity [99,109]. In support of these findings, TGR5-/- mice display impaired glucose
tolerance, whereas TGR5-overexpressing mice display enhanced GLP-1 secretion and insulin release in
response to a glucose load [99].
PXR is a nuclear receptor that acts as a xenobiotic sensor. It is highly expressed in the liver and
intestine, where it modulates the expression of several cytochromes. PXR can be activated by the toxic
bile acid LCA, but only at supraphysiological concentrations, such as those that take place during
severe cholestasis [129].
VDR is expressed at high levels in the small intestine, kidneys, osteoblasts and many types of
immune cells. Similar to PXR, also VDR is also activated by LCA as well as LCA-derived metabolites and
regulates the expression of genes involved in bile acid synthesis, conjugation, transport and metabolism.
S1PR2 is highly expressed in hepatocytes where it can be activated by taurocholate (TCA)
and other conjugated BAs, but not unconjugated BAs. The binding of conjugated BAs to S1PR2
increases sphingosine-1-phosphate (S1P) biosynthesis, while reducing ceramide, sphingomyelin and
glucosylceramide concentration [111]. In addition, bile-acid activated S1PR2 determines insulin-like
activity in the hepatic glucose metabolism, with a downregulation of the gluconeogenesis genes, PEP
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) [130].
2.3. Short Chain Fatty Acids
The human gut is able to digest and absorb many nutrients present in food, but several
carbohydrates, the so-called dietary fibres, escape digestion in the upper gastrointestinal tract and can
be fermented by the anaerobic microbial community in the caecum and colon [131]. Those include
structural non-starch polysaccharides, resistant starch and some oligosaccharides [132].
The most abundant metabolites generated by the gut microbiota from the breakdown of
undigestible carbohydrates are SCFA, defined as the fatty acids with less than six carbons, thus
spanning from formic to valeric acid. Among them, acetic, propionic and butyric acid account
for 95% of the whole SCFA. They are generally found in the colon in a ratio of 60/20/20, and their
combined concentration ranges from 50 to 150 mM [133]. Acetate is the most abundant SCFA, being
a fermentation product from pyruvate via acetyl-CoA of most anaerobic bacteria as well as being
produced by acetogenic bacteria through other pathways [134]. Propionate and butyrate are instead
produced by different gut bacteria. Specifically, propionate is mainly formed by Bacteroidetes as well as
by the Negativicutes class of Firmicutes [135], whereas butyrate is produced by several species belonging
to Ruminococcaceae and Lachnospiraceae, as well as to other families of human colonic Firmicutes [136,137].
After their production by the microbiota, SCFA are almost completely absorbed by colonic cells
through active transport, passive diffusion or in exchange with bicarbonate. Reportedly, not only the
production rate of SCFA varies throughout the large intestine [138], but also their absorption. For
instance, it has been shown that acetate absorption peaks in the distal colon [139]. Active transport is the
main route of SCFA absorption and is mediated by monocarboxylate transporters (MCT). Specifically,
MCT1 transports SCFA in a H+-dependent manner, whereas a sodium-dependent MCT1 (SMCT1 or
SLC5A8) transports SCFA anions [140].
After absorption, SCFA and particularly butyrate, are partially used as energy sources by the
colonocytes, and the fraction not metabolized is transported into portal circulation [141,142]. In the
liver, besides the use of SCFA as energy source, acetate is precursor for the synthesis of cholesterol and
fatty acids, and propionate contributes to gluconeogenesis [143]. The end result is that only about 40%,
10%, and 5% of the acetate, propionate and butyrate, respectively, produced by the microbiota reaches
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the systemic circulation. Plasma concentrations have been reported to be in the range 25–250 µM for
acetate, 1.4–13.4 µM for propionate, and 0.5–14.2 µM for butyrate [138,144].
SCFA exert several beneficial effects for gut health. SCFA, particularly butyrate, contribute to
the maintenance of barrier integrity by regulating the expression of tight junction proteins [145,146].
Additionally, acetate and butyrate stimulate mucin production in the gastrointestinal tract [147].
Moreover, SCFA can affect gastrointestinal motility through several mechanisms, including the release
of the gut hormone peptide YY (PYY) from enteroendocrine L-cells [148] and SCFA-induced serotonin
release from enterochromaffin cells (EC) [149]. SCFA can also influence appetite and food intake
by regulating not only PYY, but also leptin and ghrelin production, through mechanisms still not
clarified [150]. Glucose metabolism is also affected by SCFA, which have been shown to modulate
the plasma levels of insulin and GLP-1 [151]. Finally, SCFA and particularly butyrate mediate several
inhibitory effects on tumorigenesis, including decreased proliferation of cancer cells, anti-inflammatory
and immunomodulatory activities, thus possibly reducing the risk of colorectal cancer [133,152]. SCFA
are able to modulate biological responses of the host also in other organs including the brain, as it was
shown that SCFA can cross the blood-brain barrier [153].
Many of the effects mediated by SCFA occur through two major mechanisms: (a) a direct inhibition
of histone deacetylases (HDAC) and the consequent regulation of gene expression; (b) signalling
through orphan G protein-coupled receptors (GPR).
Acetylated histones have a less compact and more transcriptionally active chromatin, whereas
the removal of acetyl residues leads to a transcriptionally silenced chromatin [154]. HDAC remove
acetyl groups from histones; therefore, the inhibition of HDAC activity or expression can increase
gene transcription [154,155]. Several studies have demonstrated that SCFA inhibit HDAC activity,
thus they can alter gene expression in a wide variety of cells. SCFA are believed to exert this
effect by direct interaction with HDAC after entrance into the cells [156], or indirectly, through GPR
signalling [157]. Of all the SCFA, butyrate is considered the most potent inhibitor of HDAC activity,
but also propionate and acetate can also affect histone acetylation, depending on the tissue and the cell
type considered [158,159].
SCFA-mediated HDAC inhibition results in an anti-inflammatory immune phenotype [160]. SCFA
decrease the production of pro-inflammatory cytokines in macrophages [161] and peripheral blood
mononuclear cells [162] through the modulation of NF-kB [162]. SCFA, specifically butyrate, was
also shown to play a role in the suppression of inflammatory and allergic responses by inducing the
differentiation of regulatory T cells [163]. These results provide a molecular insight into the therapeutic
use of butyrate to ameliorate chronic inflammatory conditions, such as inflammatory bowel disease
(IBD) [134]. Moreover, butyrate may inhibit proliferation and induce apoptosis in colon cancer cell
lines [164].
SCFA-mediated HDAC inhibition also affects brain functions, such as behaviour, learning and
memory [150]. However, the dosage of SCFA seems to be critical to obtain such an effect, thus accurate
dose-response investigations will be required to confirm these observations.
SCFA are also involved in several interactions with the surface-exposed receptors of host cells.
The most investigated SCFA receptors are GPR41 also named free fatty acid receptor 3 (FFAR3 or
FFA3), GPR43 (FFAR2 or FFA2), and GPR109A. GPR43 recognizes all the three major SCFA [165],
whereas the affinity for GPR41 is higher for propionate than butyrate and low for acetate [166], and
GPR109A mainly interacts with butyrate [167]. GPR43 is expressed along the entire gastrointestinal
tract, mainly in the enteroendocrine L-cells producing PYY and GLP-1 [168,169], the gut hormones
involved in gut motility, satiety and glucose metabolism. SFCA have been shown to activate GPR43
in vitro, and mice deficient in GPR43 show a reduced SCFA-stimulated release of GLP-1, together
with impaired glucose tolerance [169]. GPR43 is also expressed in WAT [170,171] and its deletion in
mice results in obesity, whereas the adipose-specific overexpression of GPR43 is associated with a lean
phenotype [172]. Finally, GPR43 is also expressed in granulocytes, monocytes, dendritic cells and mast
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cells [173–175], indicating the role of SCFA in inflammatory/immune response. Indeed GPR43-/- mice
exhibit exacerbated or non-resolving inflammation in models of colitis, arthritis and asthma [176].
GPR41 is expressed in intestinal enteroendocrine L-cells, where it regulates the secretion of PYY
and GLP-1, and it is also found in adipose tissue, the pancreas, spleen, lymph nodes, bone marrow,
and peripheral blood mononuclear cells including monocytes [165,173]. GPR41 is also expressed in the
sympathetic ganglia and its activation leads to the release of NE by sympathetic neurons [177] with a
consequent increase in energy expenditure.
GPR109A is expressed in the epithelial cells of the colon, adipose tissue and inflammatory
cells. GPR109A might be involved in the anti-inflammatory/tumor suppressor actions of butyrate,
by stimulating the differentiation of regulatory and IL-10-producing T cells [167], by suppressing
the activation of nuclear factor-κB (NF-κB) and by inducing apoptosis independent of HDAC
inhibition [178].
3. Effects of Gut Microbiota-Derived Metabolites on Atherosclerosis and Cardiovascular
Risk Factors
Accumulating data indicate that a high-fat, high-cholesterol diet aggravates cardiovascular disease;
at the same time, several population-based studies have revealed that diet is a strong modulator of gut
microbiota [179], and that permanent changes in microbiota composition might be achieved through
dietary modifications [36,180]. In humans, diets rich in fat and protein correlate with an increased
abundance of Bacteroides, whereas high-fiber diets correlate with increased bacterial richness and an
abundance of Prevotella [16,181–183]. The consumption of diets composed entirely of animal products
triggers enrichment in bile tolerant bacteria (Bacteroides, Alistipes, and Bilophila) and a depletion in
Firmicutes able to metabolize plant polysaccharides (Roseburia, Eubacterium rectale, and Ruminococcus
bromii) [15]. In mice, the consumption of the so-called “Western diets”, low in fibers and enriched in
total fat, animal proteins and refined sugars, associates with a decrease in Bacteroidetes levels and an
increase in Firmicutes and Proteobacteria [184,185]. Similarly, the microbiota of children from a rural
African village shows a significant enrichment in Bacteroidetes and depletion in Firmicutes, mainly from
the genus Prevotella and Xylanibacter, compared with Italian children, whose diet is characterized by a
paucity of dietary fibre and who harbour increased levels of Enterobacteriaceae, predominantly Shigella
and Escherichia [16].
Moreover, dietary fibers stimulate mucus production from the intestinal epithelium [186], and the
dietary deficiency of fibers damages the mucus barrier being associated with an increased presence of
mucin-degrading bacteria (Akkermansia muciniphila and Bacteroides caccae) and a concomitantly reduced
presence of fibre-degrading species (Bacteroides ovatus and Eubacterium rectale) [187]. Consistent with
this, the administration to mice of a Western diet, low in fiber content, increases the penetrability of the
inner mucus layer and renders it penetrable, thus increasing the susceptibility to infections [188].
To make matters even more complicated, previous observations have demonstrated that
conventionally raised ApoE-/- mice fed a low-cholesterol diet have reduced aortic plaques compared to
germ-free ApoE-/- mice [189,190]. Conversely, after the administration of a Western diet, atherosclerosis
development in conventionally raised ApoE-/- mice was comparable to that in germ-free ApoE-/-
mice [190,191]. Thus, it can be hypothesized that the gut microbiota could have an impact on
atherosclerosis development through the production of some of the metabolites/hormones discussed
above [192].
3.1. Neurohormones and CVD
The role of catecholamines in the cardiovascular system is very well-known and, recently, has
been extensively reviewed [193]. Catecholamines mediate the activation of the sympathetic nervous
system and, through the binding to specific receptors, regulate the vascular tone [194] as well as heart
rate and contractility [195]. The high relevance of catecholamines in cardiovascular health and disease
is demonstrated by the huge number of drugs that, acting on their receptors, regulate blood pressure
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and heart function [196]. The actual literature does not provide sufficient evidence of the possible
ability of microbiota to affect peripheral catecholamine levels in such a way to influence cardiovascular
function. However, the proven ability of microorganisms to synthesize catecholamines or to interfere
with their metabolism suggests the need for further investigations in this direction.
As mentioned above, serotonin is unable to cross the blood-brain barrier. Peripherally, it is
mostly synthesized in EC cells by the enzyme TPH1, whereas TPH2 regulates serotonin central
production [197]. The pathophysiology of peripheral serotonin has been extensively studied in mice
lacking TPH1. TPH1 deficiency in mice does not alter serotonin levels in the brain, but it does
result in very low circulating serotonin concentrations [57]. When mice are maintained on high fat
diet, lack of TPH1 results in lower body weight, less adiposity [198,199] and the reduced expression
of markers of adipose tissue inflammation [200], compared with wild-type mice. Additionally,
TPH1-deficient mice display lower lipid accumulation in liver and improved glucose tolerance and
insulin sensitivity [198,199]. TPH1 deficiency also deprives platelets of their serotonin content and
reduces their reactivity [201], which results in delayed thrombus formation and lower inflammatory
cell recruitment [202]. All these observations suggest the benefit of low peripheral serotonin levels on
metabolic disorders and thrombosis, and, as a consequence, on associated CVD. Serotonin, through its
receptors, also plays a role in controlling blood pressure and in heart pathophysiology [203], being
essential for a correct cardiac development [204] and potentially involved in cardiac hypertrophy [205]
and heart valve disease [206]. The described studies and several other investigations have prompted
the development of TPH1 inhibitors as a therapeutic option for several pathological conditions [207].
Serotonin seems to affect microbiota and SCFA concentrations, as shown in homozygous and
heterozygous TPH1-deficient mice, where lower serotonin concentrations are associated with changes
in microbiota composition and reduced SCFA levels [208]. On the other hand, through SCFA and
secondary bile acids, the microbiota can stimulate serotonin production in EC cells, by upregulating
the expression of TPH1 [63,64]. Based on the above considerations, increasing serotonin levels may
have a detrimental effect on CVD. However, it should be considered that peripheral serotonin exerts a
multiplicity of metabolic functions, which include serotonylation of small G proteins, an essential step
for insulin secretion from the pancreatic β cells [209]. Further studies will be required to establish the
effects of serotonin modulation on metabolic disease and if microbiota metabolites play a beneficial or
a detrimental role in this context.
Of note, other tryptophan-derived metabolites may play a role in CVD. Kinurenine and related
metabolites are involved in the regulation of inflammation and immune response. The production of
these metabolites is regulated through the rate-limiting enzyme Indoleamine 2,3-dioxygenase 1 (IDO1).
Interestingly, human subjects with metabolic syndrome have increased IDO1 activity with consequent
higher levels of kynurenine. Furthermore, kynurenine to tryptophan ratio correlates with obesity, BMI,
and blood triglyceride levels [210].
GABA is supposed to mediate athero-protective actions. Several studies have shown that GABA
negatively modulates a variety of functional properties of several immune cells (macrophages, dendritic
cells and T cells), such as cytokine secretion, cell proliferation, phagocytic activity and chemotaxis [211].
Specifically, treatment with GABA inhibits the formation of human macrophage–derived foam cells
in vitro via a restoration of the physiological macrophage cholesterol metabolism [212]. Furthermore,
an increased plasma GABA concentration ameliorates the progression of autoimmune diseases, such
as multiple sclerosis, diabetes mellitus and rheumatoid arthritis [213,214].
An ever-growing body of research emphasizes the ability of gut microbiota-produced GABA to
influence the host, and possibly to exert a beneficial effect on atherosclerosis-predisposing conditions.
It has been recently demonstrated that fecal transplants from lean donors were able to raise plasma GABA
levels in obese individuals [215]. Furthermore, the dietary administration of the GABA-producing
Lactobacillus brevis DPC 6108 to insulin-resistant rats improved glucose homeostasis [216].
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On the other hand, as already mentioned, there are indications that germ-free mice have reduced
plasma GABA levels [66,217] and this is in accordance with the fact that germ-free ApoE-/- mice develop
more atherosclerosis than conventional mice with the same genotype [189,190].
3.2. Bile Acids and CVD
In addition to impacting the composition of gut microbiota, the consumption of a high-fat diet
modifies BA profiles and results in a significantly higher excretion of fecal secondary BAs, mainly DCA
and LCA [218,219]. However, the gut microbiota-mediated regulation of bile acids in atherogenesis
is not fully understood, mainly because conflicting data exist on the effects of FXR and TGR5 on
atherosclerosis development, several FXR- and TGR5-expressing tissues are involved, and the results
obtained so far come from studies in rodents.
FXR-/- mice fed a chow diet display increased plasma levels of high-density lipoprotein cholesterol
(HDL-C), non-HDL-C and triglycerides, increased apolipoprotein B-containing lipoprotein synthesis,
and a reduced expression of hepatic genes involved in reverse cholesterol transport compared to
wild-type mice [220]. In both the atherosclerosis-prone ApoE-/- and Ldlr-/- mice, the activation of FXR
with a synthetic agonist inhibits the diet-induced increase in non-HDL-C and triglyceridemia and
determines a near complete inhibition of aortic lesion formation [221]. In accordance, FXR-/- ApoE-/-
mice have increased blood levels of cholesterol and triglycerides, a more severe pro-atherogenic plasma
lipoprotein profile, and a more severe atherosclerosis [222,223].
Conversely, the administration of a Western diet to FXR-/- Ldlr-/- male mice leads to a reduced
atherosclerosis development as compared with Ldlr-/- mice. Double knockout mice were characterized
by reduced plasma levels of low-density lipoprotein cholesterol (LDL-C) and HDL-C, whereas
triglyceride levels were increased. FXR-/- Ldlr-/- male mice also showed a reduced expression of
CD36 in macrophages, a finding commonly associated with a reduction in foam cell formation and
atherosclerosis [224].
Likewise, the activation of TGR5 by a TGR5-specific agonist significantly reduces atherosclerosis
formation in Ldlr-/- mice, mainly through reduced macrophage activation and the production of
pro-inflammatory cytokines as the direct result of the NF-κB pathway blockade. Contrastingly, the
lack of TGR5 in Tgr5-/- Ldlr-/- mice does not significantly worsen atherosclerosis as compared with
Ldlr-/- mice [225].
Taken as a whole, the results seem to suggest that the loss of one receptor is compensated by the
presence of the other. In this respect, the simultaneous deficiency of FXR and TGR5 dramatically worsens
atherosclerosis development and aortic inflammation in Ldlr-/- mice fed a high-fat diet [226], whereas
the administration of a potent dual activator for FXR and TGR5 significantly reduces atherosclerotic
plaque formation [227].
Bile acid receptors are also expressed on endothelial cells, vascular smooth muscle cells and
cardiomyocytes, with resulting additional cardiovascular effects [228–231]. In this respect, BAs have
been shown to induce negative chronotropic effects on cardiomyocytes [229,232], and to reduce blood
pressure [233], mostly mediating vasorelaxation [234,235]. Of note, pinning the specific function of BAs
to specific receptors has been proven difficult, given the breadth of downstream function exerted by the
activations of many diverse receptors, further hampered by the vastly different chemical properties of
various BAs [236]. Differences in hydrophobicity and conjugation state, for example, result in different
amplitudes of vasodilatory effects (Figure 3) [237].
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3.3. SCFA and CVD
Dietary fibers have been considered among the approaches to help reduce obesity, as they promote
satiety [238]. Indeed, the water binding capacity, and more importantly, the fermentability of the fibers
by gut microbiota to SCFA is directly associated with a reduction of meal numbers and an increase in
inter-meal intervals.
Butyrate-producing bacteria are pivotal modulators in the regulation of inflammation, both locally
within the intestine, and on its peripheries. Butyrate is particularly important for the regulation of
the intestinal homeostasis of macrophages [239], as well as the regulation of the intestinal barrier
function [240,241]. This can be the direct consequence of the metabolism of colonic epithelial cells, which
is mainly dependent on butyrate and fatty acid oxidation: the resulting slight hypoxia can in turn induce
the expression of hypoxia inducible factor 1 (HIF-1a), which—among other functions—upregulates the
expression of tight junction genes [242]. Alternatively, or additionally, the histone deacetylase activity
displayed by butyrate has been shown to upregulate the expression of tight junction genes, as well as
that of intestinal mucins and cytokines [243–245].
The capability to modulate inflammation can partly explain the protective effects that butyrate
exerts in IBD [246], even though it has been very recently demonstrated that this is highly dependent
upon the context of both the microbiota and fiber composition, as butyrate-producing bacteria can, in
susceptible hosts, exacerbate inflammation [247]. Systemically, butyrate orchestrates the modulation of
inflammation in metabolic syndrome-related pathologies. Butyrate-producing bacteria are reduced in
diabetes [248], and butyrate supplementation is able to reduce diabetic inflammation [249]. In addition
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to the aforementioned effects on satiety, it is also believed that butyrate can enhance energy expenditure,
thus reducing obesity, by activating β3-receptor-mediated lipolysis in WAT [250]. Butyrate-producing
bacteria have recently been found to be capable of reducing atherosclerosis [251,252]. Opposing the
effects described below of the bacterial conversion of TMA into pro-atherogenic TMAO, Roseburia and
other butyrate-producing bacteria correlate with reduced lesion sizes in ApoE-/- mice. Experiments
performed in germ-free ApoE-/- mice colonized with defined communities demonstrate how Roseburia
intestinalis is able to ferment a high-fiber-content diet into butyrate, resulting in four-fold higher
levels of butyrate in the caecum, but—interestingly—not in plasma, and in reducing the extent of
plaque. The same effects are not reproduced without Roseburia intestinalis and can only be attained
through an exogenous butyrate source [251,252]. What links butyrate production to reduced plaque
size—since its concentration in plasma is unchanged as well as those of cholesterol and other lipids—is,
ultimately, the (already reviewed) positive effect of butyrate on the gut barrier function and macrophages.
The decreased permeability of the intestinal wall to LPS, resulting in a decreased systemic inflammation,
ultimately leads to a decreased expression of pro-inflammatory cytokines, resulting in a reduction
of plaque.
Even though some paradoxical effects of butyrate, such as the ones regarding IBD, have been
previously reported, and butyrate might itself be a double-edged sword [253], it is generally assumed
that an increase in butyrate-producing bacterial species might result in overall positive effects. It has
been proposed that a way to stimulate butyrate production might rely on the dietary supplementation
of carbohydrates that resist digestion by human enzymes, but can be subsequently metabolized by
colonic bacteria. This has largely proven to be an oversimplification, as it is heavily dependent on
the makeup of the microbiota, and fiber degradation is not a sure way to lead towards butyrate
production [254]. Trying to identify combinations of butyrogenic bacteria that can attack a broad range
of substrates is challenging, as many bacteria are specialized in metabolizing specific bonds: to improve
the efficacy of dietary supplements, a personal treatment tailored to each individual microbiota might
be necessary [254].
Propionate, from a nutritional standpoint, is unique among SCFA, as it can be incorporated into
glucose via gluconeogenesis, owing to its odd number of carbon atoms. However, the incorporation of
colonic-derived propionate into glucose is as low as 5.9% in humans, compared to the much higher
value of 62% of mice [255]. Very recently, a study found that propionate treatment in ApoE-/- mice
resulted in a broad range of positive effects [256]. The area of aortic lesions was reduced in mice
receiving propionate in drinking water—an effect that was dependent on the activity of regulatory
T cells, as demonstrated by their depletion. Contrary to butyrate—the preferred energy source of
colonocytes, which hampers its passage into the bloodstream, and whose distant actions are not
necessarily mediated by its increase in the plasma—propionate and acetate can freely travel across
the epithelium and reach the liver [257,258]. Even if only small amounts of propionate can be found
in circulation [257], local effects can also be ascribed to propionate, for example the tightening of the
intestinal epithelial cells via the induction of the expression of tight junctions [259]. Similar to butyrate,
propionate does appear to regulate inflammation with hormone-like properties.
The beneficial effects of propionate may also be partly dependent on a cholesterol lowering activity.
There are several reports in the literature where, spanning a period of at least 40 years, at least in
the animal model, propionate has been shown to display lipid- and cholesterol- lowering activities.
First, dietary fibers were associated with these findings [260], eventually pinning the effect down to
propionate in a rat model, where in liver reperfusion experiments propionate was shown to directly
inhibit cholesterol synthesis [261]. The literature is littered with similar reports, with recent research
making the connection between particular bacterial strains, propionate production and reduced plasma
cholesterol levels [262]. These findings do not, however, seem to be translatable into a human setting.
The dietary supplementation of 10 g of sodium propionate was unable to change the lipid metabolism
of six healthy volunteers [263]. This can be explained taking into account the diverse response of rat
and human hepatocytes: in one in vitro study, propionate was found to inhibit lipid synthesis in rat
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when given a dose of 0.1 mM, whereas a similar effect was only attained with human hepatocytes with
200 times the propionate concentration—as high as 20 mM [264]. The jury is still out on propionate
regulation of lipid metabolism: the clinical trial Safety and Efficacy of Propionate for Reduction of
LDL Cholesterol (PROPER-LDL) (https://clinicaltrials.gov/ct2/show/NCT03590496), which aims at
assessing the effects of a daily supplement of 500 mg of calcium propionate in hypercholesterolemic
patients—with serum LDL > 115 mg/dL—is scheduled for completion on 30 November 2020.
A more robust feature of propionate is its influence on satiety. Propionate plays a role in appetite
regulation: the administration of inulin-propionate ester was able to reduce food intake of almost
15% in overweight (BMI ~ 25) subjects, over a period of 24 weeks [265]. Other beneficial effects of
the treatment included the direct stimulation of colonic cells to produce PYY and GLP-1, which had
positive effects on glucose tolerance and overall energy intake.
The increase in colonic propionate is indeed a desired goal for appetite modulation but has major
drawbacks. Orally administered SCFA display very low palatability, and they are readily absorbed
in the small intestine, where L cells, responsible for the synthesis of both PYY and GLP-1 [266], are
rare. As for the case of propionate, diets with fiber supplements do not predictably or reliably increase
colonic production or circulating levels of propionate in humans because of the inherent variability in
gut microbial makeup [265]. Appropriate formulations, such as the aforementioned inulin-propionate
ester, should be used instead.
Acetate—the most abundantly produced SCFA—is efficiently absorbed in the colon [267], and
is made available to peripheral tissues, where it can either be used for lipogenesis, or immediately
oxidized for energy production [143]. Even though acetate is a ubiquitous molecule, pivotal to most
metabolic pathways, it has nevertheless been shown how acetate supplementation in a high-fiber diet
is able to reduce blood pressure [268], and stable isotope-labeled colonic acetate has been shown to
reach the central nervous system, resulting in hypothalamic neuronal activation ultimately leading to
appetite suppression (Figure 3) [269].
All the single evidences pointing towards overall beneficial effects of SCFA notwithstanding, the
integration of all individual evidences—each one thoroughly dissected in separate experiments often
performed in animal models—into a coherent picture, remains elusive. SCFA are themselves a source
of energy, contributing to lipid and glucose synthesis, and some epidemiological studies [270,271]
and—to some extent—mouse studies [35], have indicated a positive association between higher
fecal SCFA concentrations and body weight. These investigations, performed on a limited number
of subjects, were confirmed in a recent study on 441 men and women, where—after adjusting for
confounders—fecal SCFA levels were associated with increases in adiposity (increased BMI, body
fat and waist circumference) and cardiometabolic risk indicators (increased VLDL and triglycerides,
reduced HDL, increased systolic, diastolic and mean blood pressure) [272]. The absence of data on
circulating, and thus bioactive, SCFA does not allow us to draw clear conclusions. However, given
the countless combinations of human genetics (the other major determinant, along with the diet, of
the microbiota composition) and microbiota makeup, particular care should be taken when trying to
translate clear-cut results from in vitro and animal studies into the human setting. The topic, while
blooming at a fast rate, is still in its infancy, and personalized treatments, as already discussed, may
prove themselves the best approach in the long run.
3.4. Choline Metabolites and CVD
In 2011, a work by Hazen and Lusis stirred the scientific community by finding, through an unbiased
small-molecule metabolomics approach, that choline, and the products of its catabolism—produced by
gut microbiota—promoted atherosclerosis development [273]. Intestinal microbes metabolize choline
into trimethylamine (TMA), a gas at body temperature, which is further metabolized by the hepatic
flavin mono-oxygenases (FMOs), especially by FMO3, into trimethylamine oxide (TMAO) [274,275].
They demonstrated how atherosclerosis in ApoE-/- mice correlated in a dose-dependent manner with
increasing levels of dietary choline and TMAO. This effect was completely abolished by the suppression
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of the intestinal flora using an antibiotic cocktail. A potential mechanism might involve macrophages:
two scavenger receptors implicated in atherosclerosis—CD36 and SR-A1—were upregulated in
macrophages from mice fed with diets supplemented with either choline or TMAO. Once again,
treatment with antibiotics did not result in the upregulation of the same genes [273]. Later on,
it was found that TMAO also promotes vascular inflammation by eliciting the NF-κB signaling
cascade in both human aortic endothelial cells, as well as vascular smooth muscle cells [276].
Furthermore, TMAO-exposed endothelial cells were more efficient in promoting the recruitment
of activated lymphocytes.
Reportedly, red meat—whose consumption is associated with CVD—is a potential source of
TMAO, and experiments performed in healthy volunteers traced an increase in TMAO upon meat
consumption from an increased microbial metabolism of carnitine (but not choline), as well as from
reduced renal TMAO excretion [277]. This fits nicely with the previously described picture, but it must
be taken into account that fish and its related products, while correlated with a reduced atherosclerosis
risk [278,279], are a major choline source [280]. Fish might contain elevated choline levels, yet that is
balanced by omega-3 [281] and anti-atherogenic peptide content [278], whereas red meat consumption
is purportedly athero-prone for its high-salt, saturated fat content and polycyclic aromatic carcinogens
caused by high-temperature cooking [282]. It must be taken into account how these aspects are not
necessarily related to red meat.
Over the years it has been demonstrated that TMAO not only contributes to
atherosclerosis [283–288], but also to heart failure [289,290], thrombosis [291], cardiac transplant
outcome [292], and chronic kidney disease [293,294]. However, it is important to note that several
dietary trials did not find an association between the intake of choline-rich food—or circulating TMAO
levels—and CVD risk [32,295,296]. To further complicate the matter, a study demonstrated that the
administration of L-carnitine to male ApoE-/- mice transfected with human cholesteryl ester transfer
protein (hCETP) results in a significant increase in plasma TMAO levels that were surprisingly inversely
correlated with aortic lesion size in both aortic root and thoracic aorta [297].
Additionally, two studies testing the effect of dietary choline in ApoE-/- mice [190] and both Ldlr-/-
and ApoE-/- mice [298] concluded that there was no correlation between a choline supplemented
diet and atherosclerosis lesion size. However, in both studies the size of the aortic lesions was not
provided in absolute values, but it was normalized to the vessel area. This is an approach widely
used for vessel analysis in vivo [299–304], but not in histology, where post-mortem modifications may
occur, introducing experimental errors [305]. Interestingly, absolute lesion values, provided in the
supplementary information of one of the two studies [190], showed an increased lesion size in mice
fed more choline.
Trying to reconcile all the above data, it can be hypothesized that TMAO plays a role in
atherosclerosis, although not dramatic, and such effect may be masked, above all, by genetic and
dietary factors (Figure 3).
4. Conclusions
While the field of research into microbiota is still developing, accumulating data from an increasing
number of studies have highlighted an important link between gut microbiota and host pathophysiology.
Gut microbiota is strictly connected to the endocrine system, through the secretion of hormones, the
modulation of hormone release by the host, and the conversion of dietary and endogenous metabolites
into molecules with hormone-like properties that allow for the communication with peripheral organs
and tissues in the host.
The microbiota can thus influence a broad range of physiological processes, including host
behavior, appetite, energy metabolism and the immune response. As a consequence, alterations
in the distribution of the species that make up the intestinal microbiota (dysbiosis) can modify the
plasma concentrations of such molecules, resulting into a plethora of pathological states. In particular,
dysbiosis and altered plasma concentrations of primary and secondary bile acids, SCFA and TMAO
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have been linked to pathological conditions that increase the global CVD risk, such as atherosclerosis,
hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes.
Most of the results obtained so far and discussed in this review were obtained in rodents; thus,
future clinical studies will be necessary to assess the translatability of all these experimental and
sometimes conflicting results to the human setting. Nevertheless, the ongoing process of identifying
other microbiota-derived metabolites—and the modulation of gut microbiota composition and function
through dietary and pharmacological interventions, in order to tweak its endocrine potential—could
thus represent an exciting, novel opportunity to improve cardiovascular health and risk prevention.
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